icon-    folder.gif   Conference Reports for NATAP  
 
  Back grey_arrow_rt.gif
 
 
 
 
 
Cabotegravir+Rilpivirine Long-Acting Injectable PrEP at IAC 2020
 
 
  HPTN 083 FINAL RESULTS: Pre-exposure Prophylaxis containing long-acting injectable cabotegravir is safe and highly effective for cisgender men and transgender women who have sex with men - (07/08/20)
 
HPTN 083: Efficacy of Pre-exposure Prophylaxis (PrEP) containing Long-acting injectable cabotegravir (CAB-LA) is maintained across regions and key populations - (07/10/20)
 
Population pharmacokinetic (PopPK) modeling and simulation of monthly intramuscular (IM) long-acting rilpivirine (RPV LA) to inform strategies following dosing interruptions in HIV-1 infected subjects - (07/16/20)
 
FEASIBILITY OF IMPLEMENTING LONG-ACTING INJECTABLE ANTI-RETROVIRAL THERAPY TO TREAT HIV: A SURVEY OF HEALTH PROVIDERS FROM THE 13 COUNTRIES PARTICIPATING IN THE ATLAS-2M TRIAL - (07/15/20)
 
IAC 2020 Virtual: Perceived Implementation Barriers Decrease During Initial Stages of an Implementation Science Hybrid III Study (CUSTOMIZE) of Cabotegravir and Rilpivirine Long-Acting (CAB + RPV LA) in US Healthcare Settings: Healthcare Team Perspective - (07/10/20)
 
COMPASSIONATE USE OF LONG-ACTING (LA) CABOTEGRAVIR (CAB) AND RILPIVIRINE (RPV) FOR PATIENTS IN NEED OF PARENTERAL ANTIRETROVIRAL THERAPY - (07/11/20)
 
PATIENT-REPORTED OUTCOMES THROUGH WEEK 48 OF ATLAS-2M: A STUDY OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE ADMINISTERED EVERY FOUR OR EIGHT WEEKS - (07/11/20)
 
ViiV Healthcare to present new data on long-acting regimens for HIV prevention and treatment, alongside extensive insights into the evolving needs of people living with HIV at 23rd International AIDS Conference (AIDS 2020: Virtual) - PRESS RELEASE - (07/02/20)